Ethics codes and use of new and innovative drugs

  title={Ethics codes and use of new and innovative drugs},
  author={Jan Borysowski and Hans-J{\"o}rg Ehni and Andrzej G{\'o}rski},
  journal={British Journal of Clinical Pharmacology},
  pages={501 - 507}
Treatment with new and/or innovative drugs with uncertain safety and efficacy profile is associated with substantial ethical concerns. The main objective of this paper is to present guidance on the use of such drugs contained in: (i) major international codes and guidelines pertaining to medical ethics and biomedical research; (ii) national codes of medical ethics and professional conduct of the USA, Canada, Australia, New Zealand, the UK, Ireland, France and Germany. Out of the four… Expand
9 Citations

Topics from this paper

Reply to “Innovation and off‐label use, the French case and more” by Braillon and Lexchin
The scope of the review is fairly broad and encompasses not only innovative off‐label applications of drugs but also therapeutic use of investigational drugs (termed expanded access or compassionate use), and a recent meta‐epidemiological analysis showed that drugs used off‐ label are generally not less effective than those used as approved treatments for the same indication. Expand
Ethics codes and medical decision making.
Relevant amendments introduced to ethics codes could contribute to promoting of adequate standards of medical decision making (especially those regarding SDM among doctors) and should be updated or amended. Expand
COVID-19 and off label use of drugs: an ethical viewpoint
Three ways of off-label use as clinical practice or investigational use are described, one of them is pseudo-research, the other two are clinical practice and the third is investigational. Expand
Compassionate use of unauthorized drugs: Legal regulations and ethical challenges.
Practical aspects of the current legal regulations concerning compassionate use that have been introduced in the European Union, the USA, Canada and Australia, and guidelines, especially those contained in the Declaration of Helsinki are discussed, which may aid doctors in the ethical conduct of compassionate treatments. Expand
Innovation and off‐label use, the French case and more
The French Medical Council is a charity composed equally of medical and lay members and is suing for libel practitioners who claimed that homeopathy was “dangerous and fantasist”. Expand
Ethics of Phage Therapy
Discussion of compassionate use focuses on whether phage therapy is compliant with the four main principles of medical ethics including non-maleficence, beneficence, justice, and respect for the patient's autonomy. Expand
Phage therapy: Current status and perspectives
Evidence has been accumulating to suggest that phages can also exert anti‐inflammatory and immunomodulatory action which opens new pathways for the development of novel targets for PT. Expand
Overcoming Challenges to Make Bacteriophage Therapy Standard Clinical Treatment Practice for Cystic Fibrosis
In this review, insights are provided in the use of primary airway epithelial cells to represent the mucoenvironment of the CF lungs to demonstrate safety and efficacy of phage therapy. Expand
G-CSF, a ray of sunshine in the darkness for patients with alcoholic hepatitis?


Ethics review in compassionate use
Approval by a research ethics committee should be obligatory for compassionate use, and aspects of compassionate use that are important for the discussion of the role of research ethics committees in the review are presented. Expand
The ethics of using innovative therapies in the care of children.
In paediatrics, the conflict between withholding potential rescue therapy and protecting a vulnerable population's rights and welfare must be considered, and it is necessary to ensure that this innovation is conducted within an ethical framework that recognizes that the therapy is not standard. Expand
Study on off-label use of medicinal products in the European Union.
The balance between the benefits and risks that off-label use has for patients, and the regulatory framework for the off- Label use of medicines is investigated, as well as a description of the national frameworks, regulatory and other, governing off- label use of medicinal products in the various EU Member States. Expand
The Ethical Challenges of Compassionate Use.
Granting access to drugs, vaccines, biologics, and devices that have not yet been approved by governmental regulatory authorities is a growing challenge for physicians, public officials, patientExpand
Revised CIOMS International Ethical Guidelines for Health-Related Research Involving Humans.
The aim of the guidelines is to provide internationally vetted ethical principles and detailed commentary on how these principles should be applied, with particular attention to conducting research in lowand middleincome countries (LMICs). Expand
An overview of Compassionate Use Programs in the European Union member states.
Overall, this review identified CUP and its current status and legislation in 28 EU member states and suggested their willingness to adopt processes that facilitate earlier and better access to new medicines. Expand
Legal and regulatory responses to innovative treatment.
This paper discusses recent developments in Singapore and uses them as a springboard to flesh out basic regulatory issues that arise from the deployment of innovative treatment: the distinction between innovative treatment and clinical research, the adequacy of the current post hoc scrutiny of innovative therapy under existing legal principles and the need for further specialised regulatory oversight. Expand
The need to revise the Helsinki Declaration
The Macchiarini case illustrates how the 37th paragraph of the Helsinki Declaration can be misinterpreted, and emphasises the need to revise this part of the declaration to better safeguard against experimentation at the physician's own discretion. Expand
Ten common questions (and their answers) about off-label drug use.
The term off-label drug use (OLDU) is used extensively in the medical literature, continuing medical education exercises, and the media. Yet, we propose that many health care professionals have anExpand
Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments.
The ethical arguments for and against the provision of access to Phase 1 agents for terminally ill patients are reviewed, including questions about the kinds of personal sacrifices society can reasonably expect patients in clinical trials to make to ensure statistically predictive results. Expand